{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T20:09:32Z","timestamp":1781899772369,"version":"3.54.5"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002957","name":"Technische Universit\u00e4t Dresden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:p><jats:bold>Purpose:<\/jats:bold> Neurofilament light chain in serum (sNfL) has been suggested as a biomarker for the assessment of neuroaxonal damage. Since NfL are not expressed in muscle, elevated sNfL in patients with primary myopathies suggest additional nervous system involvement. To verify this hypothesis, we measured sNfL in a series of patients with myopathies.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> sNfL were determined in 62 patients with molecular proven primary myopathies in whom some nervous system involvement may be predicted: myotonic dystrophy type I and II (DM I, II) and mitochondrial disease. In addition, sNfL were measured in 8 patients with facioscapulohumeral muscular dystrophy (FSHD) and in a disease control group caused by genetic defects exclusively expressed in muscle.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> sNfL values were significantly elevated in the DM I, the DM II and the mitochondrial group, with FSHD patients showing the lowest sNfL elevations. sNfL levels in the disease control group were not different from the healthy controls. A significant correlation between repeat length and sNfL levels was found in the DM I patients, but not in the DM II patients. Mitochondrial patients with encephalopathy showed significantly higher sNfL concentrations compared to patients with only muscular symptoms.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> sNfL levels are elevated in myopathies with, based on the underlying molecular defect or clinical features, established nervous system involvement, i.e., myotonic dystrophies and mitochondrial disorders. sNfL were also raised in FSHD, where involvement of the nervous system is not usually clinically apparent. Thus, sNfL concentrations may serve as a biomarker for additional neuronal damage in primary myopathies.<\/jats:p>","DOI":"10.3389\/fnins.2021.791670","type":"journal-article","created":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T09:05:32Z","timestamp":1639731932000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Serum Neurofilament Light Chain: A Marker of Nervous System Damage in Myopathies"],"prefix":"10.3389","volume":"15","author":[{"given":"Annika","family":"Saak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Benkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Akg\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline","family":"Willemse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kuhle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjalf","family":"Ziemssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e555","DOI":"10.1212\/NXI.0000000000000555","article-title":"Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS.","volume":"6","author":"Akg\u00fcn","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756286419845567","article-title":"Advances in imaging of brain abnormalities in neuromuscular diseases.","volume":"12","author":"Angelini","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1373\/clinchem.2015.246280","article-title":"for the STARD Group, STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies.","volume":"61","author":"Bossuyt","year":"2015","journal-title":"Clin. Chem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1212\/WNL.0000000000003653","article-title":"Serum neurofilament is associated with progression of brain atrophy and disability in early MS.","volume":"88","author":"Kuhle","year":"2017","journal-title":"Neurology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1136\/jmg.2003.016048","article-title":"Variable penetrance of a familial progressive necrotising encephalopathy due to a novel tRNA(Ile) homoplasmic mutation in the mitochondrial genome.","volume":"41","author":"Limongelli","year":"2004","journal-title":"J. Med. Genet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/jns.12279","article-title":"Serum and cerebrospinal neurfilament light chain levels in patients with acquired peripheral neuropathies.","volume":"23","author":"Mariotto","year":"2018","journal-title":"J. Peripher. Nerv. Syst."},{"key":"B7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1136\/jnnp-2020-323899","article-title":"Serum neurofilament light chain predicts long-term prognosis in Guillain-Barr\u00e9 syndrome patients.","volume":"92","author":"Mart\u00edn-Aguilar","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","article-title":"Association of plasma neurofilament light with neurodegeneration in patients with alzheimer disease.","volume":"74","author":"Mattsson","year":"2017","journal-title":"JAMA Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3389\/fneur.2018.00601","article-title":"Myotonic dystrophy - a progeroid disease?","volume":"9","author":"Meinke","year":"2018","journal-title":"Front. Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e518","DOI":"10.1212\/WNL.0000000000004932et","article-title":"Plasma neurofilament light chain concentration in the inherited peripheral neuropathies.","volume":"90","author":"Sandelius","year":"2018","journal-title":"Neurology"},{"key":"B11","article-title":"Myotonic Dystrophy Type 2","author":"Schoser","year":"2006","journal-title":"GeneReviews"},{"key":"B12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1601-183X.2008.00442.x","article-title":"Cognitive function in facioscapulohumeral dystrophy correlates with the molecular defect.","volume":"8","author":"Sistiaga","year":"2009","journal-title":"Genes Brain Behav."},{"key":"B13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/jnnp-2015-311387","article-title":"Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients.","volume":"87","author":"Steinacker","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B14","first-page":"233","article-title":"Facioscapulohumeral muscular dystrophy. Multimodal evoked potentials and electroretinogram.","volume":"47","author":"St\u00fcbgen","year":"2007","journal-title":"Electromyogr. Clin. Neurophysiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/ana.26004","article-title":"Serum neurofilament light chain levels in the intensive care unit: comparison between severely ill patients with and without covid-19.","volume":"89","author":"Sutter","year":"2020","journal-title":"Ann. Neurol."},{"key":"B16","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3390\/biomedicines8110523","article-title":"Blood neurofilament light chain: the neurologist\u2019s troponin?","volume":"8","author":"Thebault","year":"2020","journal-title":"Biomedicines"},{"key":"B17","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3233\/JND-190397","article-title":"Brain structural features of myotonic dystrophy type 1 and their relationship with CTG Repeats.","volume":"6","author":"van der Plas","year":"2019","journal-title":"J. Neuromuscul. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/jns.12319","article-title":"Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy.","volume":"24","author":"Van Lieverloo","year":"2019","journal-title":"J. Peripher. Nerv. Syst."},{"key":"B19","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1212\/01.wnl.0000342121.91336.4d","article-title":"Urine heteroplasmy is the best predictor of clinical outcome in the m.3243A>G mtDNA mutation.","volume":"72","author":"Whittaker","year":"2009","journal-title":"Neurology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1038\/s41598-021-81721-7","article-title":"Neurofilament light is a novel biomarker for mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes.","volume":"11","author":"Zheng","year":"2021","journal-title":"Sci. Rep."}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2021.791670\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T09:05:39Z","timestamp":1639731939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2021.791670\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,17]]},"references-count":20,"alternative-id":["10.3389\/fnins.2021.791670"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2021.791670","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,17]]},"article-number":"791670"}}